WeissLaw LLP Files Class Action Lawsuit Against MedEquities Realty Trust, Inc.

Ein Arzt berät einen Patienten (Symbolbild). © TommL / Vetta / Getty Images https://www.gettyimages.de/

PR Newswire

NEW YORK, May 9, 2019

NEW YORK, May 9, 2019 /PRNewswire/ -- WeissLaw LLP announced that it has filed a class action on behalf of shareholders of MedEquities Realty Trust, Inc. ("MRT") (NYSE: MRT) seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed acquisition of MRT by Omega Healthcare Investors, Inc. ("Omega") (the "Proposed Transaction"). The class action was commenced in the United States District Court for the Middle District of Tennessee, Bushansky v. MedEquities Realty Trust, Inc., 3:19-cv-00231, on behalf of all persons or entities that had purchased or otherwise acquired MRT shares as of January 2, 2019, and continue to hold shares of MRT (the "Class Period").

If you own MRT shares and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Visit our website
http://www.weisslawllp.com/medequities-realty-trust-inc-action/

Or follow us on Twitter @MarketsAlert

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

On January 2, 2019, MRT and Omega issued a joint press release announcing that they had entered into an Agreement and Plan of Merger pursuant to which MRT shareholders will be entitled to receive (i) 0.235 of a share of Omega common stock, and (ii) $2.00 in cash, subject to adjustments as set forth in the merger agreement under certain limited circumstances, for each MRT common share held.

ARIVA.DE Börsen-Geflüster

Kurse

MORTONS REST. GRP (NEW)

0,00%

The complaint seeks injunctive and other relief on behalf of the named plaintiff and all MRT shareholders, and alleges that in an attempt to secure shareholder approval for the merger, the defendants filed a materially incomplete and misleading joint proxy statement/prospectus on Form S-4 with the Securities and Exchange Commission in violation of the Exchange Act. The omitted and/or misrepresented information is believed to be material to MRT shareholders' ability to make an informed decision whether to vote their shares in favor of the Proposed Transaction. The plaintiff is represented by WeissLaw, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.

If you wish to serve as lead plaintiff, you must move the Court no later than sixty (60) days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Joshua M. Rubin of WeissLaw at 888.593.4771, or by e-mail at stockinfo@weisslawllp.com. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions, recovering over a billion dollars for clients. If you have information or would like legal advice concerning possible corporate wrongdoing please email us at stockinfo@weisslawllp.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-files-class-action-lawsuit-against-medequities-realty-trust-inc-300847760.html

SOURCE WeissLaw LLP

Mehr Nachrichten zur MORTONS REST. GRP (NEW) Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.